Financials data is unavailable for this security.
View more
Year on year Sapporo Clinical Laboratory Inc 's net income deteriorated -33.14% from 568.62m to 380.16m despite relatively flat revenues. A contributing factor has been the increase in the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percent of sales).
| Gross margin | 30.15% |
|---|---|
| Net profit margin | 1.83% |
| Operating margin | 2.89% |
| Return on assets | 2.19% |
|---|---|
| Return on equity | 3.48% |
| Return on investment | 2.79% |
More ▼
Cash flow in JPYView more
In 2024, Sapporo Clinical Laboratory Inc increased its cash reserves by 8.54%, or 312.16m. The company earned 1.08bn from its operations for a Cash Flow Margin of 5.47%. In addition the company used 395.47m on investing activities and also paid 369.96m in financing cash flows.
| Cash flow per share | 188.50 |
|---|---|
| Price/Cash flow per share | 6.72 |
| Book value per share | 3,486.29 |
|---|---|
| Tangible book value per share | 3,454.09 |
More ▼
Balance sheet in JPYView more
| Current ratio | 2.20 |
|---|---|
| Quick ratio | 2.01 |
| Total debt/total equity | 0.19 |
|---|---|
| Total debt/total capital | 0.1567 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -33.06%. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is below the industry average.
| Div yield(5 year avg) | 1.50% |
|---|---|
| Div growth rate (5 year) | 18.13% |
| Payout ratio (TTM) | 20.50% |
| EPS growth(5 years) | -5.62 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -27.23 |
More ▼
